A groundbreaking clinical trial, known as CHAMP (Childhood Atropine for Myopia Progression), has demonstrated the potential of a drug therapy to slow the progression of nearsightedness in children. The three-year study found that a low-dose atropine eye drop, compared to a placebo, effectively limited changes in eyeglass prescriptions and inhibited elongation of the eye in nearsighted children aged six to 10. Nearsightedness, or myopia increases the risk of various eye conditions. The results are a significant breakthrough for the myopia research community.

Researchers Develop Smart Sensing Ring for healthcare